Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS).
暂无分享,去创建一个
J. Blay | G. Demetri | R. Maki | P. Schöffski | G. Grignani | S. Chawla | D. D’Adamo | M. Guo